We co-encapsulated rapamycin and gefitinib into chitosan nanoparticles (NP) at a reasonable ratio to tune the cellular uptake; we then coated the NP with anti-EGFR aptamers to deliver drugs preferentially to the tumor site and to minimize non-targeted delivery. The gene discussed is EGFR; the disease is neoplasm.